Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-08-29
2006-08-29
Helms, Larry R. (Department: 1641)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S007200, C436S063000, C436S086000, C436S089000, C436S173000, C436S178000, C436S501000, C436S518000, C530S300000, C530S350000, C530S387900
Reexamination Certificate
active
07097989
ABSTRACT:
The instant invention involves the use of a combination of preparatory steps in conjunction with mass spectroscopy and time-of-flight detection procedures to maximize the diversity of biopolymers which are verifiable within a particular sample. The cohort of biopolymers verified within such a sample is then viewed with reference to their ability to evidence at least one particular disease state; thereby enabling a diagnostician to gain the ability to characterize either the presence or absence of at least one disease state relative to recognition of the presence and/or the absence of the biopolymer, predict disease risk assessment, and develop therapeutic avenues against the disease.
REFERENCES:
patent: 5062935 (1991-11-01), Schlag et al.
patent: 5778895 (1998-07-01), Barnum
patent: 5849297 (1998-12-01), Harrison et al.
patent: 6020208 (2000-02-01), Hutchens et al.
patent: 6221657 (2001-04-01), Harrison et al.
patent: 448 464 (1991-09-01), None
patent: WO 90/14148 (1990-11-01), None
patent: WO 93/24834 (1993-12-01), None
patent: WO 98/07036 (1998-02-01), None
patent: WO00/49410 (2000-08-01), None
patent: WO02/088707 (2002-11-01), None
patent: WO02/088711 (2002-11-01), None
Tockman et al. “Consideration in bringing a cancer biomarker to clinical application.” Cancer Research, Suppl. vol. 52, pp. 2711s-2718s, May 1992.
Tascilar et al. Annals of Oncology 10,Suppl. 4:S107-S110, 1999.
Takahashi et al., “Rapid and Sensitive Immunoassay for the Measurement of Serum S100β Using Isoform-specific Monoclonal Antibody”, Clinical Chemistry 45, No. 8, (1999) pp. 1307-1311.
Richter et al., “Composition of the peptide fraction in human blood plasma: database of circulating human peptides”, Journal of Chromatography B; 726 (1999) pp. 25-35.
C. Weyer et al, “Insulin Action and Insulinemia are Closely Related to the Fasting Complement C3, but not Acylation Stimulating Protein Concentration”, Diabetes Care, 23(6):779-785 (Jun. 2000).
A. Figueredo et al, “Plasma C3d Levels and Ischemic Heart Disease in Type II Diabetes”, Diabetes Care, 16(2):445-449 (1993).
P. Ebeling et al, “Troglitazone Reduces Hyperglycaemia and Selectively Acute-Phase Serum Proteins in Patients with Type II Diabetes”, Diabetologia, 42(12):1433-1438 (Dec. 1999).
C. Koch et al, “A Novel Polymorphism of Human Complement Component C3 Detected by Means of a Monoclonal Antibody”, Immunogenetics, 23(5):322-325 (1986).
P. Jungblut et al, “Proteomics in Human Disease: Cancer, Heart and Infectious Diseases”, Electrophoresis, 20(10):2100-2110 (Jul. 1999).
J. Pickup et al, “NIDDM as a Disease of the Innate Immune System: Association of Acute-Phase Reactants and Interleukin-6 with Metabolic Syndrome X”, Diabetologia, 40(11):1286-1292 (Nov. 1997).
Jackowski George
Marshall John
Cook Lisa V.
Helms Larry R.
McHale & Slavin P.A.
Syn X Pharma, Inc.
LandOfFree
Complement C3 precursor biopolymer markers predictive of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Complement C3 precursor biopolymer markers predictive of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complement C3 precursor biopolymer markers predictive of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3662938